MAIA Biotechnology, Inc. ( (MAIA) ) has shared an announcement.
MAIA Biotechnology, Inc. is actively engaging with the financial community, presenting at the H.C. Wainwright Global Investment Conference and sharing updates on its website about their business and clinical progress, including a partnership with Regeneron. The company also announced promising survival data from a Phase 2 study of their cancer treatment, THIO, in Non-Small Cell Lung Cancer. However, investors are cautioned to consider the forward-looking nature of these statements, which are based on current management expectations and subject to risks and uncertainties that could cause actual results to differ.
See more data about MAIA stock on TipRanks’ Stock Analysis page.
